Cataract News and Research

Latest Cataract News and Research

People to get free vision rehabilitation surgeries with launch of 2010 China-Africa Brightness Action

The launching ceremony for the "2010 China-Africa Brightness Action" was held at Deer Jet's fix base operation (FBO), Beijing Capital International Airport on November 18.

20 Nov 2010

OptiMedica's Catalys Precision Laser System improves precision in cataract surgery

Global ophthalmic device company OptiMedica Corp. has announced that results from a clinical study of its Catalys Precision Laser System were published in the peer-reviewed journal Science Translational Medicine.

18 Nov 2010

FDA grants three years of marketing exclusivity to ISTA's BROMDAY

ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted the Company three years of marketing exclusivity for BROMDAY (bromfenac ophthalmic solution) 0.09%, as provided under the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act.

18 Nov 2010

Amgen wins Scrip Best New Drug award for Prolia

Amgen is pleased to announce that it has won the Best New Drug award for Prolia™ (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME's Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break down bone.

8 Nov 2010

Omeros third quarter net loss increases to $7.6 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced its financial results for the third quarter of 2010.

4 Nov 2010

STAAR Surgical third quarter total net sales increases 6% to $13.2 million

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported results for the third quarter ended October 1, 2010. Revenue for the period grew 6% to $13.2 million reflecting core product (IOLs and ICLs) revenue growth of 10% and a 44% decrease in defocused product revenue as compared to the third quarter of 2009.

3 Nov 2010

ISTA third quarter net revenue increases 31% to $42.0 million

ISTA Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2010. Third quarter 2010 net revenues were $42.0 million, an increase of 31% from the third quarter of 2009.

3 Nov 2010

cbm marks 10 millionth cataract surgery

Today's cataract surgery of Joyce Kaaya, 57, in Moshi, Tanzania symbolically marks the 10 millionth cataract surgery in cbm-supported programs throughout the world.

29 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

Highlights of world's largest ophthalmic education conference

Results of clinical research on new presbyopia treatments now available in Europe-and possibly available soon in the United States-were reported in today's Scientific Program of the 2010 Joint Meeting of the American Academy of Ophthalmology (AAO) and Middle East-Africa Council of Ophthalmology (MEACO). The AAO-MEACO meeting is the world's largest, most comprehensive ophthalmic education conference and is in session October 16 through 19 at McCormick Place, Chicago.

20 Oct 2010

Cataract surgery also reduces car crashes

Cataract surgery not only improves vision and quality of life for older people, but is also apparently a way to reduce the number of car crashes. The research will be presented today's at the Scientific Program of the 2010 American Academy of Ophthalmology (AAO) - Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting.

20 Oct 2010

FDA approves ISTA's sNDA for BROMDAY ophthalmic anti-inflammatory drug

ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.

18 Oct 2010

2010 AAO-MEACO meeting focuses on genetic medicine

Genetic medicine is the focus of two presentations at today's Scientific Program of the 2010 American Academy of Ophthalmology (AAO) Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting. The AAO-MEACO meeting is in session October 16 through 19 at McCormick Place, Chicago. It is the largest, most comprehensive ophthalmic education conference in the world.

18 Oct 2010

New implantable pressure sensor for patients with cataract and glaucoma

AcuMEMS, Inc. today announced the development of a new sensor for wireless intraocular pressure (IOP) monitoring of patients with co-incident cataract and glaucoma. Successful animal studies confirm the precise delivery of the implantable pressure sensor into the eye where synthetic intraocular lenses (IOL) are inserted for cataract treatment.

15 Oct 2010

OptiMedica to feature Catalys Precision Laser System at Ophthalmology annual meeting

Global ophthalmic device company OptiMedica Corp. has announced that its Catalys Precision Laser System will be featured as part of four clinical presentations at the American Academy of Ophthalmology annual meeting in Chicago on October 16, 17 and 18.

13 Oct 2010

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Ocular Therapeutix, Inc. announced today the completion of a successful Proof of Principle clinical study with their novel sustained drug delivery moxifloxacin punctum plug.

13 Oct 2010

ISTA Pharmaceuticals announces Phase 1/2 clinical study results of bepotastine besilate nasal spray

ISTA Pharmaceuticals, Inc., today announced positive preliminary results from a Phase 1/2 clinical study of bepotastine besilate nasal spray conducted in Canada for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies.

6 Oct 2010

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

ISTA Pharmaceuticals, Inc. today highlighted results from the Company's REMURA (bromfenac ophthalmic solution for dry eye) Phase 2 clinical study.

27 Sep 2010

FDA approves OZURDEX implant for uveitis treatment

Allergan, Inc. today announced that the United States Food and Drug Administration (FDA) has approved OZURDEX (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye.

27 Sep 2010

South Carolina optometrists provide eye, vision assessments for infants through InfantSEE

Due to the overwhelming number of children with eye and vision problems across the United States, South Carolina optometrists are devoting appointments to no-cost, comprehensive eye and vision assessments for infants between six to 12 months of age through InfantSEE.

21 Sep 2010